Top PCD Pharma Franchise for Artesunate Injection Seize a critical opportunity in the anti-malarial market by partnering with a leading pharmaceutical manufacturer. Salvus Pharma, a WHO-GMP and ISO certified company, is proud to offer a premier PCD Pharma franchise opportunity for our Artesunate for Injection I.P. 60mg. This life-saving medication, presented under the brand name Sonate, is the first-line treatment for severe malaria as recommended by the World Health Organization (WHO), creating a vital and consistent demand in endemic regions. Why Choose a Franchise for Artesunate Injection with Salvus Pharma? Your partnership with Salvus Pharma is a strategic investment in quality healthcare and business growth. We provide: Exceptional Product Quality: Our Artesunate Injection is produced under stringent sterile conditions, ensuring a potent, pure, and reliable product that meets the critical demands of emergency medical care. Exclusive Monopoly Rights: We grant our franchise associates exclusive rights to market and distribute Artesunate Injection in their agreed-upon territory. This empowers you to build a strong market presence without facing internal competition. Clinical & Marketing Support: We provide comprehensive support with detailed product literature, scientific information, and promotional tools designed to help you effectively communicate the life-saving benefits of Artesunate to doctors, clinics, and hospitals. Uninterrupted Supply Chain: With a robust production and distribution network, we guarantee a steady and timely supply of Sonate injection, ensuring you can meet the urgent needs of patients with severe malaria.